Abstract
Recurrent and unpredictable episodes of vaso-occlusion are the hallmark of sickle cell disease. Symptomatic management and prevention of these events using the fetal hemoglobin-reactivating agent hydroxyurea are currently the mainstay of treatment. Discoveries over the past 2 decades have highlighted the important contributions of various cellular and soluble participants in the vaso-occlusive cascade. The role of these elements and the opportunities for therapeutic intervention are summarized in this review.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 362-369 |
| Number of pages | 8 |
| Journal | Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program |
| Volume | 2013 |
| DOIs | |
| State | Published - 2013 |
| Externally published | Yes |
ASJC Scopus subject areas
- Hematology